Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Overview

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Overview

This experiment addresses a critical evidence gap: while iron accumulation in the substantia nigra is a well-documented pathological feature of Parkinson's disease (PD), the role of astrocytic ferritin iron metabolism in disease progression remains poorly understood. [Astrocytes](/entities/astrocytes) are the primary iron-storing cells in the brain and play a crucial role in neuronal iron homeostasis, yet therapeutic targeting of astrocyte iron metabolism has not been systematically explored.

This experiment will characterize astrocyte ferritin dysfunction in PD and test whether enhancing astrocytic iron export or reducing iron storage can provide neuroprotection.

Hypothesis

Primary Hypothesis: Dysfunctional astrocytic ferritin iron metabolism contributes to dopaminergic neuron death in PD, and pharmacological enhancement of astrocytic iron export (via ferroportin) or reduction of astrocytic iron storage (via ferritin modulation) will reduce oxidative stress and provide neuroprotection.

Secondary Hypotheses:

Specific Aims

Aim 1: Characterization of Astrocytic Iron Metabolism in PD

• Compare ferritin and ferroportin expression in astrocytes from PD patient iPSCs vs. healthy controls
• Measure intracellular iron accumulation using live-cell iron sensors
• Quantify iron release rates under various conditions

Aim 2: Iron-Aggregation Link Studies

• Test whether iron released from astrocytes promotes alpha-synuclein nucleation
• Use seeded aggregation assays with astrocyte-conditioned media
• Determine iron species responsible (Fe2+ vs. Fe3+)

Aim 3: Small Molecule Screening for Iron Metabolism Modulation

• Screen 300+ compounds for ability to enhance ferroportin expression
• Screen for ferritin degradation enhancers
• Test in astrocyte-neuron co-culture systems

Aim 4: In Vivo Validation

• Test top 2 lead compounds in MPTP mouse model of PD
• Measure: dopaminergic neuron survival, motor behavior, iron levels, alpha-synuclein pathology
• Establish PK/PD relationships

Detailed Protocol

Phase 1: Astrocyte Characterization (Months 1-6)

Cell Models

• iPSC-derived astrocytes from 5 PD patients ([LRRK2](/entities/lrrk2) G2019S, [GBA1](/entities/gba), idiopathic)
• iPSC-derived astrocytes from 5 age-matched healthy controls
• Primary human astrocytes (commercially available)

Assays

• Western blot for ferritin (H and L subunits), ferroportin, transferrin receptor
• Immunofluorescence for cellular iron localization (Perls staining)
• Live-cell imaging with FeR reporter (calcium-based iron sensor)
• Iron release assays using 55Fe radiolabeled transferrin

Key Reagents

• Primary antibodies: Ferritin (Abcam ab69090), Ferroportin (Novus Biologicals NBP1-21502)
• iPSC lines: WiCell lines, authenticated
• Iron sensors: FeR-Green1 (Thermo Fisher)

Phase 2: Iron-Aggregation Studies (Months 4-10)

Experimental Design

• Collect conditioned media from PD vs. control astrocytes
• Add to alpha-synuclein seed amplification assays (RT-QuIC)
• Test with/without iron chelation (deferoxamine, clioquinol)

Assays

• RT-QuIC for alpha-synuclein aggregation kinetics
• Thioflavin T fluorescence assays
• Western blot for alpha-synuclein phosphorylation (pS129)

Phase 3: Drug Screening (Months 6-14)

Compound Libraries

• FDA-approved drug library (200 compounds)
• Known iron chelators (50 compounds)
• Ferroportin activators (50 compounds)

Screening Platform

• Primary screen: Ferroportin promoter-luciferase reporter in astrocytes
• Secondary: Iron release assay using 55Fe
• Tertiary: Astrocyte-neuron co-culture neuroprotection assay

Lead Compounds

• Test top 20 hits in astrocyte-neuron co-cultures
• Measure: neuronal viability, iron levels, oxidative stress markers

Phase 4: In Vivo Validation (Months 12-24)

Animal Models

• C57BL/6 mice, MPTP-induced PD model
• Treatment groups: Vehicle, Lead compound 1, Lead compound 2, Positive control (deferoxamine)

Endpoints

• Stereological counting of tyrosine hydroxylase (TH)+ [neurons](/entities/neurons) in substantia nigra
• Rotarod and cylinder test for motor function
• Perls staining for brain iron levels
• pS129 alpha-synuclein immunohistochemistry
• Biochemical: iron, ferritin, ferroportin in brain tissue

Reagents and Costs

Personnel (Total: $480,000)

• Principal Investigator (20% effort): $60,000
• Postdoctoral Researcher (2): $180,000
• Research Technician: $90,000
• Graduate Student: $60,000
• Research Coordinator: $90,000

Equipment (Total: $85,000)

• Live-cell imaging system (IncuCyte): $45,000
• Plate reader (fluorescence/luminescence): $25,000
• Cryostat: $15,000

Reagents (Total: $195,000)

• iPSC lines and differentiation kits: $45,000
• Antibodies: $35,000
• Compound libraries: $40,000
• Iron sensors and tracers: $25,000
• Animal costs (mice, housing): $35,000
• Reagents for biochemistry: $15,000

Other (Total: $140,000)

• Animal facility costs: $60,000
• Bioinformatics/analysis: $30,000
• Publication costs: $15,000
• Contingency (15%): $35,000

Total Estimated Cost: $900,000

Suggested Labs/Investigators

Primary Expertise (Iron Metabolism)

• Dr. Michael Aschner (Albert Einstein College of Medicine) - Brain iron metabolism
• Dr. James Connor (Penn State) - Ferritin and iron in neurodegeneration
• Dr. Rajesh Ambasudhan (UT Southwestern) - Astrocyte biology

PD Research

• Dr. Birgit Lang (University of Tuebingen) - LRRK2 and iron
• Dr. Kalyan J. Outeiro (University of Exeter) - Alpha-synuclein and iron
• Dr. Ashley Zhang (UCLA) - iPSC models of PD

Drug Development

• Dr. Stefano L. Sensi (University of Chieti) - Iron chelation therapy
• Dr. Peng Lei (Shanghai Jiao Tong) - Ferroportin biology

International/Diverse

• Dr. Masahiko Takada (Tokyo Metropolitan Institute) - Non-human primate models
• Dr. Suman Dutta (All India Institute of Medical Sciences) - Population genetics of iron-related genes
• Dr. Claudia Duran (University of Sao Paulo) - Latin American PD cohorts

Timeline

• Phase 1 (Months 1-6): Astrocyte characterization - $180,000
• Phase 2 (Months 4-10): Iron-aggregation studies - $150,000
• Phase 3 (Months 6-14): Drug screening - $220,000
• Phase 4 (Months 12-24): In vivo validation - $250,000
• Analysis (Months 22-26): Data integration - $50,000
• Contingency: $50,000

Scoring

Scientific Value (SV): 9/10

• Directly addresses iron accumulation, a hallmark of PD pathogenesis
• Bridges astrocyte biology with neurodegeneration
• Potential to identify novel therapeutic targets

Feasibility (F): 7/10

• iPSC-derived astrocyte models are well-established
• Iron assays are routine
• In vivo validation is standard

Novelty (N): 9/10

• First systematic study of astrocytic ferritin in PD
• Ferroportin as therapeutic target is underexplored
• Iron-alpha-synuclein link in astrocyte context is novel

Disease Impact (DI): 10/10

• Iron dysregulation is a core PD pathological feature
• Addresses unmet need for disease-modifying therapies
• Potential for combination with existing treatments

Reach (R): 7/10

• Primarily PD-focused
• May have implications for other neurodegenerative diseases with iron dysregulation
• Findings could inform iron metabolism in aging

Cost Efficiency (CE): 7/10

• Moderate cost for comprehensive study
• Drug repurposing approach reduces development costs
• In vivo validation adds cost but is necessary

Time Efficiency (TE): 7/10

• 26 months is reasonable for this scope
• Some phases can run in parallel
• In vivo validation is time-intensive but essential

Evidence Base (EB): 8/10

• Strong preclinical evidence for iron's role in PD
• Astrocyte involvement is emerging area
• Some gaps in understanding astrocyte-neuron iron transfer

Addresses Uncertainty (AU): 9/10

• Tests whether astrocyte iron dysregulation is cause or consequence
• Determines therapeutic potential of iron modulation
• Clarifies iron-alpha-synuclein relationship

Translation Potential (TP): 9/10

• Drug repurposing for iron metabolism is feasible
• Ferroportin modulators already in development for other conditions
• Clear path to IND-enabling studies if leads identified

Weighted Score: 82 × 1.4 = 114.8/140

Cross-Links to Relevant Wiki Pages

• [Astrocytes](/cell-types/astrocytes) - Cell type being studied
• [Parkinson's Disease](/diseases/parkinsons-disease) - Target disease
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Pathology link
• [Iron Dysregulation](/mechanisms/iron-dysregulation-neurodegeneration) - Mechanism
• [Ferroportin](/entities/slc40a1-ferroportin) - Therapeutic target
• [Substantia Nigra](/brain-regions/substantia-nigra) - Brain region
• [Neuroprotective A2 Astrocytes](/cell-types/neuroprotective-a2-astrocytes) - Potential phenotype
• [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration) - Downstream effect
• [GBA1](/genes/gba1) - PD gene with iron link
• [LRRK2](/genes/lrrk2) - PD gene with iron link

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease discovered through SciDEX knowledge graph analysis: